Literature DB >> 24389308

Effect of busulfan on JAK2V617F allele burden.

Maria Luigia Randi1, Claudia Santarossa, Edoardo Peroni, Elisabetta Cosi, Elena Duner, Irene Bertozzi, Fabrizio Fabris.   

Abstract

Entities:  

Keywords:  JAK2; busulfan

Mesh：

Substances：

Year:  2014        PMID： 24389308      PMCID： PMC3943332          DOI： 10.3324/haematol.2013.103051

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Bruno Cassinat; Sylvie Chevret; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Bernard Grandchamp; Christine Chomienne; Pierre Fenaux
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

2.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

3.  JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Authors:  Emil T Kuriakose; Stefani Gjoni; Y Lynn Wang; Ruth Baumann; Amy V Jones; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

4.  Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)

Authors:  I Brodsky
Journal:  Am J Clin Oncol       Date:  1998-02       Impact factor: 2.339

5.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

6.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

Authors:  Guido Finazzi; Vanesa Caruso; Roberto Marchioli; Giovanni Capnist; Teodoro Chisesi; Carlo Finelli; Luigi Gugliotta; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Raphael Marilus; Carlo Patrono; Enrico Maria Pogliani; Maria Luigia Randi; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  Blood       Date:  2004-12-07       Impact factor: 22.113

Review 7.  Front-line therapy in polycythemia vera and essential thrombocythemia.

Authors:  Tiziano Barbui; Maria Chiara Finazzi; Guido Finazzi
Journal:  Blood Rev       Date:  2012-07-10       Impact factor: 8.250

8.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors:  Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

9.  Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-06       Impact factor: 10.047
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.